Head-to-head treatment comparisons in real-world populations, designed to isolate treatment effects from the confounding inherent in observational data.

Historically controlled comparator groups constructed from real-world data to support single-arm trials, with rigorous attention to time zero, eligibility alignment, and bias protection.

Trial emulation frameworks that bring the design discipline of randomized trials to observational analyses, supporting label expansion and regulatory submissions.

Pre-comparative assessments that evaluate whether treatment groups are sufficiently comparable before a study is run, catching bias problems early, not after results are in.

How patients actually use treatments in practice: initiation, switching, discontinuation, and the downstream outcome consequences of each.

Resource use, expenditure, and burden of illness analyses that inform payer and HTA submissions as well as internal commercial decision-making.

Disease natural history, incidence, prevalence, and population characterization studies, often the foundation for every study type above.

Targeted investigations of specific patient segments where standard population-level findings don't apply and where the clinical or regulatory stakes are highest.